BioCentury | Apr 8, 2013
Financial News

ViroCyt financial update

...capital round, bringing the total raised in the round to about $5 million. Existing investor High Country Venture...
BioCentury | Jan 21, 2013
Financial News

ViroCyt completes venture financing

...Denver, Colo. Business: Supply/Service Date completed: 11/14/12 Type: Venture financing Raised: $3 million Investors: High Country Venture...
BioCentury | Nov 21, 2011
Financial News

Mosaic Biosciences completes venture financing

...Musculoskeletal Date completed: 7/1/11 Type: Venture financing Raised: Not disclosed Investors: Morgenthaler Ventures; HealthCare Ventures; High Country Venture WIR...
BioCentury | Aug 30, 2010
Financial News

Taligen Therapeutics financial update

...tranche the company has closed on $36 million. Existing investors Clarus; Alta Partners; Sanderling; and High Country Venture...
BioCentury | Aug 24, 2010
Financial News

Taligen raises $10 million

...tranche the company has closed on $36 million. Existing investors Clarus; Alta Partners; Sanderling; and High Country Venture...
BioCentury | Aug 1, 2008
Financial News

Sierra raises $21.5M

...in a series A round co-led by HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners. High Country Venture...
BioCentury | Feb 11, 2008
Finance

Ebb & Flow

...was led by Alta Partners and Clarus, with participation from existing investors Sanderling; Tango; and High Country Venture...
BioCentury | Feb 2, 2008
Financial News

Taligen completes first tranche of series B

...a series B round led by Alta Partners and Clarus. Existing investors Sanderling; Tango; and High Country Venture...
BioCentury | Aug 13, 2007
Emerging Company Profile

Corporate Profile

Taligen Therapeutics Inc. Aurora, Colo. Technology: Regulation of the alternative complement pathway Disease focus: Inflammation Clinical status: Preclinical Founded: 2004 by Michael Holers and Woodruff Emlen University collaborators: University of Colorado at Denver and Medical...
Items per page:
1 - 9 of 9
BioCentury | Apr 8, 2013
Financial News

ViroCyt financial update

...capital round, bringing the total raised in the round to about $5 million. Existing investor High Country Venture...
BioCentury | Jan 21, 2013
Financial News

ViroCyt completes venture financing

...Denver, Colo. Business: Supply/Service Date completed: 11/14/12 Type: Venture financing Raised: $3 million Investors: High Country Venture...
BioCentury | Nov 21, 2011
Financial News

Mosaic Biosciences completes venture financing

...Musculoskeletal Date completed: 7/1/11 Type: Venture financing Raised: Not disclosed Investors: Morgenthaler Ventures; HealthCare Ventures; High Country Venture WIR...
BioCentury | Aug 30, 2010
Financial News

Taligen Therapeutics financial update

...tranche the company has closed on $36 million. Existing investors Clarus; Alta Partners; Sanderling; and High Country Venture...
BioCentury | Aug 24, 2010
Financial News

Taligen raises $10 million

...tranche the company has closed on $36 million. Existing investors Clarus; Alta Partners; Sanderling; and High Country Venture...
BioCentury | Aug 1, 2008
Financial News

Sierra raises $21.5M

...in a series A round co-led by HealthCare Ventures; Morgenthaler Ventures; and Sequel Venture Partners. High Country Venture...
BioCentury | Feb 11, 2008
Finance

Ebb & Flow

...was led by Alta Partners and Clarus, with participation from existing investors Sanderling; Tango; and High Country Venture...
BioCentury | Feb 2, 2008
Financial News

Taligen completes first tranche of series B

...a series B round led by Alta Partners and Clarus. Existing investors Sanderling; Tango; and High Country Venture...
BioCentury | Aug 13, 2007
Emerging Company Profile

Corporate Profile

Taligen Therapeutics Inc. Aurora, Colo. Technology: Regulation of the alternative complement pathway Disease focus: Inflammation Clinical status: Preclinical Founded: 2004 by Michael Holers and Woodruff Emlen University collaborators: University of Colorado at Denver and Medical...
Items per page:
1 - 9 of 9